News | January 03, 2025
Veeda Group rebrands as Veeda Lifesciences
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
DOVBLERON marks the 13th addition to Innovent’s commercial portfolio
MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria
SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage
Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Puri is an accomplished leader and financial sector veteran with over four decades of experience
Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH
The transaction is expected to result in approximately $175 million to support further development of IMG-007
Subscribe To Our Newsletter & Stay Updated
